New dosing data could improve tuberculosis treatment outcomes for drug-resistant cases

Researchers have mapped how the body processes cycloserine, a crucial antibiotic for multidrug-resistant tuberculosis, offering the first standardized dosing guidance for this hard-to-treat infection. The findings could help clinicians optimize treatment effectiveness while reducing side effects, potentially improving cure rates for a disease that kills thousands annually despite available drugs.

Originaltitel: Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens